Olga currently leads a Takeda Pharmaceuticals development team responsible for establishing robust and scalable biotherapeutic purification processes in support of late-stage pipeline programs along with bioconjugation processes for early and late stage projects. Olga’s prior experience includes oversight for development of upstream, downstream, and bioconjugation processes for antibodies and antibody-derived products spanning pre-clinical stage through launch (along with life-cycle management). She holds a BS in Chemical Engineering from UC Berkeley and a PhD in Chemical Engineering from UT Austin where her research focused on therapeutic enzyme engineering for oncology applications. Prior to Takeda and her graduate work, Olga also spent time at Genentech in the late stage purification process development group.